KPV: The Anti-Inflammatory Signal Without the Tan

The short version

KPV is a three-amino-acid piece cut from the tail end of a hormone the pituitary gland already makes: alpha-melanocyte-stimulating hormone (alpha-MSH), the same hormone responsible for skin tanning and pigment. Researchers found this small fragment keeps the anti-inflammatory part of alpha-MSH's job while dropping the pigment-darkening part — which made it interesting as a possible anti-inflammatory tool that would not change how skin looks.

Almost everything known about KPV comes from cells in a dish and from mice, not from people. Studies in mouse models of colitis — an inflamed, ulcerated gut lining — show that KPV calms the immune signaling driving the damage, and that a specialized gut transporter called PepT1 actively pulls the peptide into inflamed intestinal cells, where ordinary digestion would otherwise break a free peptide apart ^[8][9][10]. There are no completed human trials of KPV for any condition. This page reports the animal and cell evidence honestly, and says so plainly where it stops.

What it is

KPV — lysine-proline-valine, or Lys-Pro-Val — is a linear tripeptide corresponding to residues 11 through 13, the C-terminal end, of alpha-melanocyte-stimulating hormone. Its formula is C16H30N4O4. It is also referred to in the literature as alpha-MSH(11-13) or the C-terminal tripeptide of alpha-MSH. Unlike GHK-Cu, KPV carries no bound metal ion and is not marketed as a cosmetic ingredient — it exists almost entirely as a laboratory research compound.

How it works

KPV retains alpha-MSH's anti-inflammatory signaling while losing the parent hormone's pigment-producing (melanogenic) action. In research models, it dampens inflammation primarily by suppressing NF-kB and MAP-kinase signaling pathways and reducing the production of pro-inflammatory cytokines such as IL-1beta and TNF-alpha. In the gut specifically, KPV is taken up directly into epithelial cells through a di/tripeptide transporter called PepT1 (gene SLC15A1) — a transporter that is upregulated precisely where intestinal tissue is inflamed, which is one reason researchers have focused on KPV as a gut-targeted anti-inflammatory candidate rather than a systemic one. Its documented mechanism targets are the PepT1 transporter itself, the NF-kB transcriptional machinery, MAP kinases, and the pro-inflammatory cytokine networks those pathways drive.

What the research shows

Targeted nanodrug delivery. A 2024 study combined KPV with the immunosuppressant FK506 in a PepT1-targeted nanoparticle and tested it in mice with both acute and chronic colitis; the combination improved outcomes in both models beyond either agent alone, restoring tight-junction proteins between gut cells and lowering inflammatory cytokines ^[8].

Oral nanoparticle delivery. A 2017 study delivered KPV orally via hyaluronic-acid-functionalized nanoparticles embedded in a chitosan/alginate hydrogel, in mice with DSS-induced colitis. The targeted formulation reduced colitis severity more effectively than a non-targeted version, better preventing mucosal damage and downregulating TNF-alpha, and accelerated mucosal healing ^[9].

The founding mechanism paper. A 2008 Gastroenterology study established that KPV is transported into human intestinal epithelial cells via PepT1, and that nanomolar concentrations of KPV inhibit NF-kB and MAP-kinase inflammatory signaling and reduce cytokine secretion in both epithelial and immune cells; orally administered KPV reduced the severity of two different chemically induced colitis models in mice ^[10].

Confirming the anti-inflammatory action in vivo. A separate 2008 study found KPV reduced colonic inflammation in mice with earlier recovery, lower markers of inflammatory cell infiltration, and — notably — retained its activity even in mice lacking the MC1R receptor that alpha-MSH normally signals through, indicating KPV's anti-inflammatory action works through a different pathway than pigment signaling does ^[11].

The broader review. A comprehensive 2008 review situates KPV within a family of related tripeptides showing protective effects across fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway, arthritic, and organ-injury models in animals — describing KPV specifically as an anti-inflammatory alternative to full alpha-MSH precisely because it preserves the anti-inflammatory signal while dropping the pigmentary one ^[12].

Reported effects, cautions & safety

Unlike GHK-Cu and TB-500, KPV has no meaningful body of community-reported experience to draw on here — not because nobody has tried it, but because the compound has essentially no completed human trial record and a comparatively thin community-use footprint compared with the other two, so there is no comparable set of anecdotal benefit or side-effect reports to summarize honestly. That absence is itself worth naming: it is easy to find KPV marketed online for gut health, skin, and general anti-inflammatory use, and that marketing runs well ahead of any human evidence, whether clinical or anecdotal.

Cited cautions: No published human clinical trials of KPV exist for any use — the entire efficacy literature is in vitro and animal, chiefly murine colitis models, so human dosing, efficacy, and safety are all unestablished ^[10][11]. Free KPV is a small tripeptide broken down quickly by digestive and blood enzymes, with no validated human pharmacokinetic data; a substantial share of the current research effort is formulation work aimed at keeping it intact long enough to act at all ^[8][9]. Marketing of KPV for gut health, skin, or general anti-inflammatory use outruns the underlying evidence, which remains mechanistic and preclinical rather than clinical. Although KPV is derived from alpha-MSH, it should be clearly distinguished from melanocortin agonists marketed for pigmentation or tanning — KPV's defining feature in the research literature is anti-inflammatory action specifically without a pigmentary effect ^[12]. KPV is sold by chemical suppliers strictly for laboratory research use and carries no approved drug or dietary-supplement status in any major jurisdiction.

Where it fits in Recovery & Tissue Repair

KPV occupies the earliest, most preclinical position of the three peptides on this desk — the mechanistic story is unusually clean (an anti-inflammatory fragment that keeps its parent hormone's calming effect and drops its pigment effect), but it has not yet been tested in a single human. That puts it in direct contrast with GHK-Cu, which has small but real human trials behind it, and with TB-500, whose commercial fragment at least borrows evidence from a larger, human-studied relative even if that borrowing is contested. See the full comparison for how the three line up on evidence, legal status, and the caution that matters most for each.